StageZero Life Sciences (TSX:SZLS) 3-Year EBITDA Growth Rate : -14.50% (As of Sep. 2023)

View and export this data going back to 2001. Start your Free Trial

What is StageZero Life Sciences 3-Year EBITDA Growth Rate?

StageZero Life Sciences's EBITDA per Share for the three months ended in Sep. 2023 was C$-0.01.

During the past 3 years, the average EBITDA Per Share Growth Rate was -14.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 8.30% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 27.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of StageZero Life Sciences was 62.40% per year. The lowest was -322.30% per year. And the median was 14.50% per year.

Competitive Comparison of StageZero Life Sciences's 3-Year EBITDA Growth Rate

For the Diagnostics & Research subindustry, StageZero Life Sciences's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

StageZero Life Sciences's 3-Year EBITDA Growth Rate Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, StageZero Life Sciences's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where StageZero Life Sciences's 3-Year EBITDA Growth Rate falls into.

StageZero Life Sciences 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

StageZero Life Sciences (TSX:SZLS) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

StageZero Life Sciences 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of StageZero Life Sciences's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

StageZero Life Sciences (TSX:SZLS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » StageZero Life Sciences Ltd (TSX:SZLS) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

SZLSF:USA 61N1:Germany

Address

70 East Beaver Creek Road, Unit 30, Richmond Hill, ON, CAN, L4B 3B2

Website

https://www.stagezerolifesciences.com

StageZero Life Sciences Ltd is a vertically integrated healthcare company at the nexus of three sectors of healthcare; Early Cancer Detection, Liquid Biopsy, and Global Telehealth. It is focused on minimizing the risk of cancer and other chronic diseases through early detection and intervention. It continues to develop and commercialize proprietary molecular diagnostic tests for the early detection of diseases and personalized health management, with a focus on cancer-related indications. It has developed a proprietary platform technology, the Sentinel Principle, to identify novel biomarkers from whole blood. The Company's lead product, Aristotle, is a blood-based molecular diagnostic assessment that can detect an individual's current risk for potentially having a variety of cancers.

StageZero Life Sciences (TSX:SZLS) Headlines

No Headlines